{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-066782","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2026-06-09T20:05:24+00:00","discovered_at":"2026-06-09T20:07:00.365463+00:00","generated_at":"2026-06-09T20:08:58.599412+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jasper Therapeutics receives Nasdaq bid price deficiency notice; 180 days to cure","bullets":["On June 3, 2026, Nasdaq notified Jasper that its common stock bid price closed below $1.00 for 30 consecutive business days.","Company has until November 30, 2026 to regain compliance by achieving $1.00+ close for at least 10 consecutive days.","If not cured by Nov 30, Jasper may qualify for an additional 180-day period subject to other listing standards and potential reverse stock split.","Failure to cure could result in delisting of common stock and warrants from Nasdaq Capital Market.","Jasper intends to monitor bid price and consider options including a reverse stock split."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-066782","json":"https://secwatch.observer/filing/0001213900-26-066782.json","markdown":"https://secwatch.observer/filing/0001213900-26-066782.md","text":"https://secwatch.observer/filing/0001213900-26-066782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026066782/0001213900-26-066782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026066782/ea0294010-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T20:08:58.599412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5936e952d97fc8aebd9525d38fec6595494dafdf","claim":"Jasper Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"June 3, 2026, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 30, 2026, to regain compliance. The N","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026066782/0001213900-26-066782-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}